Last reviewed · How we verify
Lansoprazole Triple Therapy
Inhibits the H+/K+ ATPase enzyme in the gastric parietal cells
Inhibits the H+/K+ ATPase enzyme in the gastric parietal cells Used for Gastroesophageal reflux disease, Peptic ulcer disease.
At a glance
| Generic name | Lansoprazole Triple Therapy |
|---|---|
| Sponsor | HK inno.N Corporation |
| Drug class | Proton pump inhibitor |
| Target | H+/K+ ATPase |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | Phase 2 |
Mechanism of action
This leads to a decrease in gastric acid secretion, which helps to heal and prevent ulcers.
Approved indications
- Gastroesophageal reflux disease
- Peptic ulcer disease
Common side effects
- Headache
- Diarrhea
- Nausea
- Abdominal pain
- Dizziness
Key clinical trials
- CURE-H. Pylori: A Trial on the Combination of Anti-Ulcerants and Levofloxacin-Based Therapy for Helicobacter Pylori Eradication (PHASE4)
- The Effect of Vitamin D Supplement as Adjuvant Therapy in Eradication of Helicobacter Pylori Infection (PHASE3)
- Gastric Cancer Prevention in the Family Members by Helicobacter Pylori Eradication (PHASE3)
- Vonoprazan-Based Triple Therapy in Comparison With Extended Sequential Therapy (PHASE4)
- Exploratory Study to Standard Triple Therapy With Tegoprazan(by Dose) in H. Pylori Positive Patients (PHASE2)
- Recurrence Rate Comparison Between Esomeprazole and Lansoprazole in Eradicating Helicobacter Pylori Infection Among Children (PHASE2, PHASE3)
- Comparison of Vonoprazan-based Versus Lansoprazole-based Triple Therapy, High Dose Dual Therapy, Bismuth and Non-bismuth Quadruple Therapy in the First-line Treatment of Helicobacter Pylori Infection (PHASE4)
- Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With Helicobacter Pylori Infection (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lansoprazole Triple Therapy CI brief — competitive landscape report
- Lansoprazole Triple Therapy updates RSS · CI watch RSS
- HK inno.N Corporation portfolio CI